Xiaoyan Michelle Zhang - 22 Nov 2021 Form 3 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
Chief Scientific Officer
Signature
/s/ Douglas R. Carlson, as Attorney-in-Fact for Xiaoyan Michelle Zhang
Issuer symbol
IKNA
Transactions as of
22 Nov 2021
Net transactions value
$0
Form type
3
Filing time
23 Nov 2021, 19:58:41 UTC
Next filing
14 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IKNA Common Stock 44,475 22 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IKNA Stock Option (Right to Buy) 22 Nov 2021 Common Stock 26,473 $2.15 Direct F1
holding IKNA Stock Option (Right to Buy) 22 Nov 2021 Common Stock 35,792 $4.15 Direct F2
holding IKNA Stock Option (Right to Buy) 22 Nov 2021 Common Stock 19,427 $4.15 Direct F3
holding IKNA Stock Option (Right to Buy) 22 Nov 2021 Common Stock 55,912 $7.87 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2 25% of the shares subject to this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3 25% of the shares subject to this option vested and became exercisable on September 30, 2020 with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4 25% of the shares subject to this option shall vest and become exercisable on February 12, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney